Loading clinical trials...
Loading clinical trials...
A Phase II Trial of ZD 1839 (IRESSA) (NSC #715055) in the Treatment of Persistent or Recurrent Endometrial Carcinoma
Conditions
Interventions
Gefitinib
Laboratory Biomarker Analysis
Locations
1
United States
Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States
Start Date
June 1, 2002
Primary Completion Date
September 1, 2004
Completion Date
July 1, 2013
Last Updated
July 23, 2019
NCT02684227
NCT01199250
NCT01164735
NCT02996825
NCT00729586
NCT00006903
Lead Sponsor
National Cancer Institute (NCI)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions